Atlas Trials

Relapsed Adult AML

23 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Relapsed Adult AML

RecordFirmDate
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia (NCT05237258)Massachusetts General Hospital2022-06-01
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML (NCT05305859)The First Affiliated Hospital of Xiamen University2022-01-12
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT05029141)The First Affiliated Hospital of Soochow University2021-09-01
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE (NCT05193448)French Innovative Leukemia Organisation2021-07-05
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML (NCT04722952)The First Affiliated Hospital of Soochow University2021-05-01
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML (NCT04139434)Newave Pharmaceutical Inc2020-07-06
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) (NCT04330820)Technische Universität Dresden2020-04-06
Natural Killer Cell (CYNK-001) Infusions in Adults with AML (NCT04310592)Celularity Incorporated2020-03-12
Venetoclax and Lintuzumab-Ac225 in AML Patients (NCT03867682)Actinium Pharmaceuticals2020-01-15
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT03848754)Medical College of Wisconsin2019-05-24
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03850574)Aptose Biosciences Inc.2019-03-11
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) (NCT03091933)Ciusss de L'Est de l'Île de Montréal2017-02-06
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation (NCT03245424)Agios Pharmaceuticals, Inc.

Track Relapsed Adult AML automatically

Every clearance here is in the API, with alerts when new ones post.